Christopher Hite - 16 May 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Role: EVP & Vice Chairman
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite
Issuer symbol: RPRX
Transactions as of: 16 May 2025
Net transactions value: $0
Form type: 4
Filing time: 20 May 2025, 16:54:54 UTC
Previous filing: 09 May 2025
Next filing: 08 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hite Christopher	EVP & Vice Chairman	C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK	/s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite	20 May 2025	0001814238

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RPRX	Class E Ordinary Shares	Award	$0	+1,238,789		$0.000000	1,238,789	16 May 2025	Class A Ordinary Shares	1,238,789	$0.000000	See Footnote (1)(2)	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.
F2	Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

Content

Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.

Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.